Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-03. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
The surgeon measures the dimensions (length, width, depth) of the nasal wound, and then delineates them upon the nasal septum, and, if possible, incorporates an additional margin of 3–5 mm of width to the wound measurements; furthermore, the base of the mucosal tissue flap should be at least 1.5-cm wide. The surgeon then makes two parallel incisions along the floor and the roof of the nasal septum; the incisions converge anteriorly, towards the front of the nasal spine. Using an elevator, the flap is dissected in a sub-mucoperichondrial plane. The (far) distal edge of the flap is cut with a right-angle Beaver blade, and then is transposed into the wound. The exposed cartilages will reepithelialise (regenerate the epithelium), provided the opposite (contralateral) side of the septal mucosa is undisturbed. A technical variant of the septal mucosal flap technique is the trap-door flap, which is used to reconstruct one side of the upper half of the nasal lining. It is emplaced in the contralateral nasal cavity, as a superiorly based septal mucosal flap of rectangular shape, like that of a "trap-door". This septomucosal flap variant is a random flap with its pedicle based at the junction of the septum and the lateral nasal skeleton. The surgeon elevates the flap of septal mucosa to the roof of the nasal septum, and then traverses it into the contralateral (opposite) nasal cavity through a slit made by removing a small, narrow portion of the dorsal roof of the septum. Afterwards, the septomucosal flap is stretched across the wound in the mucosal lining of the lateral nose.
The two substrates of this enzyme are (+)-cis-sabinol and oxidised nicotinamide adenine dinucleotide (NAD+. Its 3 products are (+)-sabinone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (+)-cis-sabinol:NAD+ oxidoreductase. This enzyme is also called (+)-cis-sabinol dehydrogenase.
=== Tt dependence on ELP structure === The transition temperature of an ELP depends to a certain extent on the identity of the "X" residue found at the fourth position of the pentapeptide monomeric unit. Residues that are highly hydrophobic, such as leucine and phenylalanine, tend to decrease the transition temperature. On the other hand, residues that are highly hydrophilic, such as serine and glutamine, tend to increase the transition temperature. The presence of a potentially charged residue at the "X" position will determine how the ELP responds to varying pHs, with glutamic acid and aspartic acid raising the Tt at pH values in which the residues are deprotonated and lysine and arginine raising the Tt at pH values in which the residues are protonated. The pH needs to be compatible with the charged states of these amino acids in order to raise the Tt. Also higher molecular mass ELPs and higher concentrations of ELPs in solution make it much easier for the polymer to form aggregates, in effect lowering the experimental Tt.
Sources: en.wikipedia.org
== Mechanism of action == D-Ribose-L-cysteine functions as a cysteine prodrug, delivering cysteine in a chemically protected form that may resist premature oxidation. After cellular uptake, enzymatic cleavage releases free L-cysteine, which can then enter the γ-glutamyl cycle for glutathione synthesis. This mechanism differs from N-acetylcysteine, which relies on de-acetylation and exhibits different absorption and metabolic characteristics. While both compounds ultimately increase cysteine availability, direct comparative data in humans remain limited.
=== Obesity === Obesity is a global epidemic health problem and has received considerable attention as a major public hazard. Obesity is a chronic pathological and costly disease of abnormal or excessive fat accumulation in the body. Studies indicate that 5-HT2C receptor activation will regulate appetite and food consumption, most likely by promoting satiety through appetite suppression by activation of 5-HT2C. Consequently, selective agents with high affinity for this receptor over 5-HT2B and 5-HT22A are being developed for the treatment of obesity.
The broadcast pattern covered an area of about 100 degrees in a roughly fan-shaped area, with a smaller side lobe to the rear, courtesy of the reflectors, and much smaller ones to the sides. When the signal reflected off the ground it underwent a ½ wavelength phase-change, which caused it to interfere with the direct signal. The result was a series of vertically stacked lobes about 5 degrees wide from 1 degree off the ground to the vertical. The system was later expanded by adding another set of four additional antennas closer to the ground, wired in a similar fashion. The receiver consisted of an Adcock array consisting of four 240 foot (73 m) tall wooden towers arranged at the corners of a square. Each tower had three sets (originally two) of receiver antennas, one at 45, 95 and 215 feet off the ground. The mean height of the transmitter stack was 215 feet, which is why the topmost antenna was positioned at the same altitude in order to produce a reception pattern that was identical to the transmission. A set of motor-driven mechanical switches allowed the operator to select which antenna was active. The output of the selected antenna on each of the four towers was sent to a single radiogoniometer system (not Watt's own huff-duff solution). By connecting the antennas together in X-Y pairs the horizontal bearing could be measured, while connecting together the upper and lower antennas allowed the same goniometer to be used to measure the vertical angle. Two physical layout plans were used, either 'East Coast' or 'West Coast'.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.